Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is being evaluated in clinical research involving obesity and metabolic disorders.

The Hubio Pharm product is listed at 10 mg. The supplied information does not establish its dosage form, package quantity, formulation, or storage requirements.

Retatrutide is not an FDA-approved active ingredient in an approved medicine, and FDA enforcement documents have addressed retatrutide products marketed for human use.